Stifel Starts Vitae Pharmaceuticals (VTAE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Wedbush Starts Vitae Pharmaceuticals (VTAE) at Outperform
October 20, 2014 8:01 AM EDTWedbush initiated coverage on Vitae Pharmaceuticals (NASDAQ: VTAE) with an Outperform rating and a price target of $21.00.
Analyst Liana Moussatos said, "Vitae is a clinical-stage emerging pharmaceutical company leveraging its proprietary Contour® structure-based drug design platform to discover and develop optimized orally-dosed small-molecule drug... More
JMP Securities Starts Vitae Pharmaceuticals (VTAE) at Market Outperform
October 20, 2014 7:56 AM EDTJMP Securities initiated coverage on Vitae Pharmaceuticals (NASDAQ: VTAE) with an Market Outperform rating and a price target of $15.00.
For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.
Shares of Vitae Pharmaceuticals closed at $6.30 yesterday.
... MoreUPDATE: BMO Capital Starts Vitae Pharmaceuticals (VTAE) at Outperform
October 20, 2014 7:55 AM EDT(Updated - October 20, 2014 9:13 AM EDT)
BMO Capital initiated coverage on Vitae Pharmaceuticals (NASDAQ: VTAE) with an Outperform rating and a price target of $11.00.
Analyst Jim Birchenough said, "Our favorable rating is supported by an efficient structure-based drug design platform, a deep pipeline of highly selective small-molecule drugs across multiple therapeutic categories and... More
